Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1922–1927. doi: 10.1054/bjoc.2001.2192

RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer

T Oshikiri 1, Y Hida 1, M Miyamoto 1, H Hashida 1, K Katoh 1, M Suzuoki 1, Y Nakakubo 1, K Hiraoka 1, T Shinohara 2, T Itoh 3, S Kondo 1, H Katoh 1
PMCID: PMC2364016  PMID: 11747335

Abstract

Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) induces apoptosis in immune cells bearing the RCAS1 receptor. We sought to determine RCAS1 involvement in the origin and progression of gallbladder cancer, and also implications of RCAS1 for patient survival. RCAS1 expression was examined immunohistochemically in 110 surgically resected gallbladder specimens. The gallbladders represented 20 cases of cholecystitis with no associated pancreaticobiliary maljunction; 23 cases of cholecystitis with pancreaticobiliary maljunction; 14 cases of adenomyomatosis; 7 adenomas; and 46 cancers. High expression of RCAS1 (immunoreactivity in over 25% of cells) was observed in 32 of the 46 cancers (70%), but not in other diseases, including pre-cancerous conditions. RCAS1 immunoreactivity was associated with depth of tumour invasion (P = 0.0180), lymph node metastasis (P = 0.0033), lymphatic involvement (P = 0.0104), venous involvement (P = 0.0224), perineural involvement (P = 0.0351) and stage by the tumour, nodes and metastases (TNM) classification (P = 0.0026). Thus, RCAS1 expression may be a relatively late event in gallbladder carcinogenesis possibly promoting tumour progression. Cox regression multivariate analysis demonstrated RCAS1 positivity to be an independent negative predictor for survival (P = 0.0337; risk ratio, 12.690; 95% confidence interval, 1.216–132.423). High expression of RCAS1 significantly correlated with tumour progression and predicted poor outcome in gallbladder cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: RCAS1, gallbladder cancer, carcinogenesis, immunohistochemistry

Full Text

The Full Text of this article is available as a PDF (104.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajiki T., Fujimori T., Onoyama H., Yamamoto M., Kitazawa S., Maeda S., Saitoh Y. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut. 1996 Mar;38(3):426–429. doi: 10.1136/gut.38.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ajiki T., Onoyama H., Yamamoto M., Asaka K., Fujimori T., Maeda S., Saitoh Y. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology. 1996 May-Jun;43(9):521–526. [PubMed] [Google Scholar]
  3. Anayama T., Furihata M., Ishikawa T., Ohtsuki Y., Ogoshi S. Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer. 1998 Aug 21;79(4):439–443. doi: 10.1002/(sici)1097-0215(19980821)79:4<439::aid-ijc22>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  4. Bartlett D. L., Fong Y., Fortner J. G., Brennan M. F., Blumgart L. H. Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg. 1996 Nov;224(5):639–646. doi: 10.1097/00000658-199611000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benoist S., Panis Y., Fagniez P. L. Long-term results after curative resection for carcinoma of the gallbladder. French University Association for Surgical Research. Am J Surg. 1998 Feb;175(2):118–122. doi: 10.1016/s0002-9610(97)00269-9. [DOI] [PubMed] [Google Scholar]
  6. Casey J. L., Pedley R. B., King D. J., Green A. J., Yarranton G. T., Begent R. H. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. Br J Cancer. 1999 Nov;81(6):972–980. doi: 10.1038/sj.bjc.6690795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Iwasaki T., Nakashima M., Watanabe T., Yamamoto S., Inoue Y., Yamanaka H., Matsumura A., Iuchi K., Mori T., Okada M. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int J Cancer. 2000 Nov 20;89(6):488–493. doi: 10.1002/1097-0215(20001120)89:6<488::aid-ijc4>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  8. Kaku T., Sonoda K., Kamura T., Hirakawa T., Sakai K., Amada S., Ogawa S., Kobayashi H., Nakashima M., Watanabe T. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. Clin Cancer Res. 1999 Jun;5(6):1449–1453. [PubMed] [Google Scholar]
  9. Katoh T., Nakai T., Hayashi S., Satake T. Noninvasive carcinoma of the gallbladder arising in localized type adenomyomatosis. Am J Gastroenterol. 1988 Jun;83(6):670–674. [PubMed] [Google Scholar]
  10. Kozuka S., Tsubone N., Yasui A., Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer. 1982 Nov 15;50(10):2226–2234. doi: 10.1002/1097-0142(19821115)50:10<2226::aid-cncr2820501043>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  11. Lindén O., Tennvall J., Cavallin-Ståhl E., Darte L., Garkavij M., Lindner K. J., Ljungberg M., Ohlsson T., Sjögreen K., Wingårdh K. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. Clin Cancer Res. 1999 Oct;5(10 Suppl):3287s–3291s. [PubMed] [Google Scholar]
  12. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 Feb;3(2):231–234. doi: 10.1038/nm0297-231. [DOI] [PubMed] [Google Scholar]
  13. Nakashima M., Sonoda K., Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med. 1999 Aug;5(8):938–942. doi: 10.1038/11383. [DOI] [PubMed] [Google Scholar]
  14. Ogura Y., Mizumoto R., Isaji S., Kusuda T., Matsuda S., Tabata M. Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg. 1991 May-Jun;15(3):337–343. doi: 10.1007/BF01658725. [DOI] [PubMed] [Google Scholar]
  15. Ootani T., Shirai Y., Tsukada K., Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992 Jun 1;69(11):2647–2652. doi: 10.1002/1097-0142(19920601)69:11<2647::aid-cncr2820691105>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  16. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  17. Shimada H., Endo I., Togo S., Nakano A., Izumi T., Nakagawara G. The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer. 1997 Mar 1;79(5):892–899. doi: 10.1002/(sici)1097-0142(19970301)79:5<892::aid-cncr4>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  18. Sonoda K., Nakashima M., Kaku T., Kamura T., Nakano H., Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer. 1996 Apr 15;77(8):1501–1509. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1501::AID-CNCR12>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES